8月7日，翰森制药盘中上涨3.6%，报32.82港元，成交额3.3亿港元。
消息面上，翰森制药8月6日公告，其自主研发的1类新药HS-10582片已获中国国家药品监督管理局签发的《药物临床试验批准通知书》，拟用于治疗成人原发性高胆固醇血症和混合型血脂异常。该药物获批进入临床阶段，为公司在心血管代谢领域管线布局再添新进展。此外，公司近期研发成果密集兑现，核心品种HS-20093此前已在小细胞肺癌及骨肉瘤两项III期临床中达到主要终点，里昂维持"跑赢大市"评级并将目标价上调至42港元。公司将于8月26日召开董事会审议中期业绩。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.